← BridgeBio Pharma, Inc.
| Annual Trend | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Net loss | ($43.8m) | ($169.5m) | ($288.6m) | ($505.5m) | ($586.5m) | ($484.7m) | ($653.3m) | ($543.3m) | ($732.9m) | ($1.5m) | — | |
| Net loss from equity method investments | — | $275k | $20.9m | — | — | $0 | $0 | $31.2m | $72.6m | — | — | |
| Net Income (Loss) Available to Common Stockholders, Basic | — | ($130.7m) |
($260.6m)
-99.30%
|
($448.7m)
-72.20%
|
($562.5m)
-25.36%
|
($481.2m)
+14.46%
|
($643.2m)
-33.67%
|
($535.8m)
+16.70%
|
($724.9m)
-35.31%
|
— | — | |
| Net Income (Loss), Including Portion Attributable to Noncontrolling Interest | — | ($169.5m) | ($288.6m) | ($505.5m) | ($586.5m) | ($484.7m) | ($653.3m) | ($543.3m) | ($732.9m) | — | — | |
| Net Income (Loss) Attributable to Noncontrolling Interest | — | ($38.7m) | ($28.0m) | ($56.8m) | ($23.9m) | ($3.5m) | ($10.0m) | ($7.6m) | ($8.0m) | — | — | |
| Depreciation, Depletion and Amortization | — | — | $859k | $1.5m | $5.8m | $6.8m | $6.5m | $6.1m | $5.4m | — | $5.3m | |
| Depreciation | — | — | $859k | $1.5m | $5.8m | $6.8m | $6.5m | $3.7m | $2.5m | — | $5.3m | |
| Amortization of Debt Issuance Costs and Discounts | — | — | — | — | $3.3m | $3.6m | $3.7m | $3.8m | $6.0m | — | — | |
| Amortization of Intangible Assets | — | — | — | $986k | $2.6m | $2.4m | $2.4m | $2.4m | $2.7m | — | — | |
| Amortization of debt discount and issuance costs | — | — | — | — | — | — | $8.9m | $7.5m | $6.0m | — | — | |
| Depreciation (Note 4) | — | — | — | — | — | $18k | $18k | $0 | $0 | — | $5.3m | |
| Amortization and depreciation of equipment and intangible assets | — | — | — | $986k | $158k | $18k | — | — | — | — | — | |
| Amortization of right-of-use assets | — | — | — | $422k | $185k | — | — | — | — | — | — | |
| Depreciation Amortization Depletion | — | — | — | — | — | $6.8m | $6.5m | $6.1m | $5.4m | — | $5.3m | |
| Deferred Income Tax Expense (Benefit) | — | — | — | — | — | — | — | — | $0 | — | — | |
| Share-based Payment Arrangement, Noncash Expense | — | $6.1m | $21.4m | $58.5m | $99.5m | $91.6m | $108.7m | $95.8m | $133.0m | — | $140.4m | |
| Payment, Tax Withholding, Share-based Payment Arrangement | — | — | — | $714k | $4.7m | $1.6m | $6.9m | $7.5m | $14.2m | — | — | |
| Share-based Payment Arrangement, Expense | — | $6.1m | $21.4m | $58.5m | $105.6m | $93.8m | $115.0m | $113.9m | $136.9m | — | $140.4m | |
| Stock-based compensation | $1.8m | $6.1m | $21.4m | $58.5m | $99.5m | $91.6m | $108.7m | $95.8m | $133.0m | — | $140.4m | |
| Share-based payments (Notes 11(b), 11(c), 11(d) and 14) | — | — | — | $1.6m | $827k | $1.2m | $951k | $500k | $2.0m | $170k | — | |
| Operating Lease, Impairment Loss | — | — | — | — | $2.6m | — | — | — | $0 | — | — | |
| Loss on impairment of intangible assets | — | — | — | $6.6m | $12.1m | — | — | — | — | — | — | |
| Asset Impairment Charge | — | — | — | — | $0 | $12.7m | $0 | $271k | — | — | $271k | |
| Income (Loss) from Equity Method Investments | — | ($275k) | ($20.9m) | — | — | $0 | $0 | ($31.2m) | ($72.6m) | — | — | |
| Nonoperating Income (Expense) | — | $14.2m | ($22.3m) | ($31.0m) | ($9.8m) | $27.6m | ($45.9m) | $50.8m | ($209.1m) | — | — | |
| Other Nonoperating Income (Expense) | — | — | — | $1.6m | $35.8m | ($7.5m) | $17.4m | $12.3m | $43.1m | — | — | |
| Noncash income from equity method investments | — | — | — | — | — | — | $0 | $0 | ($8.8m) | — | — | |
| Earnings (Loss)es From Equity Investments | — | — | — | — | — | $0 | $0 | $31.2m | $72.6m | — | $75.3m | |
| Changes in operating assets and liabilities: | ||||||||||||
| Change In Working Capital | — | — | — | — | — | $28.1m | $5.1m | $32.0m | ($51.1m) | — | ($59.6m) | |
| Increase (Decrease) in Accounts Receivable | — | — | — | — | — | — | — | $3.0m | $134.7m | — | ($90.0m) | |
| Accounts receivable, net | — | — | — | — | — | $15.2m | $15.3m | ($3.0m) | ($134.7m) | — | ($90.0m) | |
| Change in Accounts Receivable | — | — | — | — | — | $181k | $310k | ($22k) | $28k | $9k | — | |
| Change In Receivables | — | — | — | — | — | $15.2m | $15.3m | ($3.0m) | ($134.7m) | — | ($90.0m) | |
| Changes In Account Receivables | — | — | — | — | — | $15.2m | $15.3m | ($3.0m) | ($134.7m) | — | ($90.0m) | |
| Increase (Decrease) in Inventories | — | — | — | — | — | — | — | — | $25.3m | — | ($29.2m) | |
| Inventories | — | — | — | — | — | — | $0 | $0 | ($25.3m) | — | ($29.2m) | |
| Change In Inventory | — | — | — | — | — | — | $0 | $0 | ($25.3m) | — | ($29.2m) | |
| Increase (Decrease) in Accounts Payable | $1.6m | $16.7m | ($4.7m) | ($735k) | $2.8m | ($349k) | $2.8m | $1.5m | $26.6m | — | $1.9m | |
| Accounts payable and accrued liabilities | — | — | — | $1.1m | ($994k) | ($1.2m) | $2.2m | ($702k) | $109k | $242k | $1.9m | |
| Change In Payables And Accrued Expense | — | — | — | — | — | ($14.7m) | $727k | $27.2m | $56.8m | — | $1.9m | |
| Accrued compensation and benefits | $1.1m | $3.4m | $9.3m | $8.6m | $7.4m | ($2.4m) | $7.8m | $17.0m | $23.0m | — | — | |
| Accrued research and development liabilities | $2.6m | $5.8m | $12.0m | $6.2m | $11.2m | ($4.3m) | ($9.9m) | $8.7m | $7.2m | — | — | |
| Deferred revenue | — | — | — | $0 | $0 | $15.3m | ($5.4m) | $21.9m | ($11.4m) | — | — | |
| Change In Accrued Expense | — | — | — | — | — | ($14.4m) | ($2.1m) | $25.7m | $30.2m | — | $25.7m | |
| Prepaid expenses and other current assets | ($4.3m) | ($6.1m) | ($13.5m) | ($7.1m) | ($4.3m) | $7.7m | ($2.7m) | ($13.9m) | ($8.8m) | — | — | |
| Other assets | ($92k) | ($843k) | ($16.9m) | ($2.1m) | ($9.8m) | $11.0m | ($1.5m) | $1.5m | $1.1m | — | — | |
| Other liabilities | $268k | $182k | ($65k) | — | — | — | $3.5m | $4.2m | $77.8m | — | — | |
| Restricted cash — Included in “Prepaid expenses and other current assets” | — | — | — | — | — | — | $16.7m | $126k | $550k | — | — | |
| Restricted cash — Included in “Other assets” | — | — | — | — | — | — | $2.1m | $2.0m | $1.5m | — | — | |
| Prepaids and other current assets | — | — | — | $10k | ($270k) | $10k | $595k | ($199k) | $43k | $661 | — | |
| Change In Other Current Assets | — | — | — | — | — | $11.0m | ($1.5m) | $1.5m | $1.1m | — | ($2.3m) | |
| Change In Other Current Liabilities | — | — | — | — | — | ($6.2m) | ($4.8m) | ($5.9m) | ($6.5m) | — | ($5.3m) | |
| Net Cash Provided by (Used in) Operating Activities | ($40.5m) |
($136.6m)
-237.49%
|
($253.6m)
-85.58%
|
($399.7m)
-57.62%
|
($497.9m)
-24.57%
|
($419.5m)
+15.75%
|
($527.7m)
-25.80%
|
($520.7m)
+1.33%
|
($445.9m)
+14.37%
|
($625k)
+99.86%
|
($444.0m)
-70880.97%
|
|
| Cash flows from investing activities: | ||||||||||||
| Payments to Acquire Property, Plant, and Equipment | ($464k) | $2.2m | $2.6m | $7.5m | $13.2m | $4.8m | $1.3m | $933k | $1.1m | — | ($8.1m) | |
| Unpaid property and equipment | — | — | — | $1.1m | $563k | $47k | $100k | $279k | $43k | — | — | |
| Debt Securities, Available-for-sale, Realized Gain (Loss) | — | — | — | — | $0 | $0 | $0 | — | — | — | — | |
| Purchases of marketable securities | — | — | ($212.9m) | ($287.9m) | ($589.9m) | ($137.5m) | ($29.7m) | ($93.8m) | ($28.2m) | — | — | |
| Maturities of marketable securities | — | — | — | $249.1m | $380.2m | $479.7m | $82.5m | $95.0m | $11.0m | — | — | |
| Purchases of investments in equity securities | — | — | — | $0 | ($53.4m) | ($55.6m) | ($107.5m) | ($20.3m) | $0 | — | — | |
| Proceeds from sales of investments in equity securities | — | — | — | $0 | $34.1m | $52.8m | $110.6m | $63.2m | $0 | — | — | |
| Payments for (Proceeds from) Other Investing Activities | — | — | — | — | — | $0 | — | — | — | — | — | |
| Net Other Investing Changes | — | — | — | — | $13.7m | $120.0m | ($503k) | — | — | — | ($140k) | |
| Net Cash from Investing Activities | — | — | — | ($1.1m) | ($72k) | — | — | — | — | — | — | |
| Net Cash Provided by (Used in) Investing Activities | ($464k) | ($21.0m) | ($217.3m) | ($53.0m) | ($200.8m) | $453.1m | $54.0m | $60.8m | ($24.5m) | — | ($65.6m) | |
| Cash flows from financing activities: | ||||||||||||
| Repayments of Long-term Debt | — | $1.1m | — | — | $124.1m | $20.5m | $0 | $473.4m | — | — | $0 | |
| Gain (Loss) on Extinguishment of Debt | — | — | — | — | ($3.3m) | $0 | $0 | ($26.6m) | ($21.2m) | — | — | |
| Loss on extinguishments of debt | — | — | — | $0 | $3.3m | $0 | $0 | $26.6m | $21.2m | — | — | |
| Gain on extinguishment/forgiveness of debts (Note 14) | — | — | — | — | — | — | $0 | ($469k) | ($110k) | ($150k) | — | |
| Proceeds from Debt Issuance | — | — | — | — | — | — | — | $0 | $0 | $411k | — | |
| Loss on debt modification (Note 6) | — | — | — | — | — | ($56k) | $197k | $0 | $0 | — | — | |
| Gain on forgiveness of debts (Note 15) | — | — | — | — | — | $0 | $0 | ($469k) | — | — | — | |
| Issuance Of Debt | — | — | — | — | — | $0 | $0 | $450.0m | $575.0m | — | $632.5m | |
| Long Term Debt Issuance | — | — | — | — | — | $0 | $0 | $450.0m | $575.0m | — | $632.5m | |
| Long Term Debt Payments | — | — | — | — | — | ($20.5m) | $0 | ($473.4m) | ($459.0m) | — | $0 | |
| Net Issuance Payments Of Debt | — | — | — | — | — | ($20.5m) | $0 | ($23.4m) | $116.0m | — | $632.5m | |
| Net Long Term Debt Issuance | — | — | — | — | — | ($20.5m) | $0 | ($23.4m) | $116.0m | — | $632.5m | |
| Repayment Of Debt | — | — | — | — | — | ($20.5m) | $0 | ($473.4m) | ($459.0m) | — | $0 | |
| Payments for Repurchase of Common Stock | — | — | — | $75.0m | $200.0m | $0 | $0 | $0 | $48.3m | — | — | |
| Proceeds from Issuance of Common Stock | — | — | — | $0 | $0 | $4.9m | $144.0m | $314.7m | $0 | — | ($18k) | |
| Repurchase of common stock | — | — | — | ($75.0m) | ($200.0m) | $0 | $0 | $0 | ($48.3m) | — | — | |
| Proceeds from common stock issuances under ESPP | — | — | $921k | $1.2m | $3.8m | $2.6m | $3.4m | $4.5m | $6.4m | — | — | |
| Common Stock Issuance | — | — | — | — | — | $4.9m | $449.8m | $314.7m | $0 | — | ($18k) | |
| Common Stock Payments | — | — | — | — | — | ($1.6m) | ($6.9m) | ($7.5m) | ($62.5m) | — | ($99.0m) | |
| Issuance Of Capital Stock | — | — | — | — | — | $4.9m | $449.8m | $314.7m | $0 | — | ($18k) | |
| Net Common Stock Issuance | — | — | — | — | — | $3.3m | $442.9m | $307.2m | ($62.5m) | — | ($99.0m) | |
| Repurchase Of Capital Stock | — | — | — | — | — | ($1.6m) | ($6.9m) | ($7.5m) | ($62.5m) | — | ($99.0m) | |
| Dividends paid | — | — | $1 | — | — | — | — | — | — | — | — | |
| Proceeds from special cash dividends received from an investment in equity securities | — | — | — | — | — | $0 | $0 | $25.7m | $2.3m | — | — | |
| Dividends Received CFI | — | — | — | — | — | $0 | $0 | $25.7m | $2.3m | — | $0 | |
| Proceeds from (Payments for) Other Financing Activities | — | — | — | — | — | $837k | $0 | $0 | — | — | — | |
| Net Other Financing Charges | — | — | — | — | — | $837k | ($801k) | $456.5m | $271.6m | — | $258.9m | |
| Net Cash from Financing Activities | — | — | — | $12.2m |
$190k
-98.45%
|
$11.2m
+5824.85%
|
$0
-100.00%
|
$300k |
$1.2m
+308.07%
|
$0
-100.00%
|
— | |
| Net Cash Provided by (Used in) Financing Activities | $113.0m |
$501.5m
+343.91%
|
$398.8m
-20.49%
|
$447.2m
+12.14%
|
$736.4m
+64.68%
|
($13.1m)
-101.78%
|
$451.5m
+3537.91%
|
$748.5m
+65.76%
|
$359.3m
-52.00%
|
$629k
-99.82%
|
$848.9m
+134797.01%
|
|
| Net increase (decrease) in cash, cash equivalents, and restricted cash | $72.0m | $343.9m | ($72.0m) | ($5.5m) | $37.7m | $20.5m | ($22.2m) | $288.5m | ($111.1m) | — | — | |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect | $72.0m | $343.9m | ($72.0m) | ($5.5m) | $37.7m | $20.5m | ($22.2m) | $288.5m | ($111.1m) | — | $882.0m | |
| Cash, cash equivalents, and restricted cash at beginning of year | $92.4m | $436.2m | $364.2m | $358.7m | $396.4m | $416.9m | $394.7m | $683.2m | $572.1m | — | — | |
| Cash - beginning of year | — | — | — | — | $155k | $174k | $8k | $8k | $37k | $8k | — | |
| Cash - beginning of period | — | — | $75k | $75k | $3.3m | $155k | — | — | — | — | — | |
| Beginning Cash Position | — | — | — | — | — | $396.4m | $416.9m | $394.7m | $683.2m | — | $542.7m | |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | $72.0m | $343.9m | ($72.0m) | ($5.5m) | $37.7m | $416.9m | $394.7m | $683.2m | $572.1m | — | $882.0m | |
| Total cash, cash equivalents and restricted cash at end of years shown on the consolidated statements of cash flows | — | — | — | $358.7m | $396.4m | $416.9m | $394.7m | $683.2m | $572.1m | — | — | |
| Additional Supplementary Disclosures | ||||||||||||
| Additional Supplementary Disclosures | ||||||||||||
| Proceeds from Stock Options Exercised | — | $440k | $1.8m | $12.9m | $16.6m | $666k | $6.0m | $3.7m | $27.7m | — | — | |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating Activities | — | $1.6m | $6.1m | $15.3m | $29.8m | $54.4m | $61.1m | $91.3m | $43.7m | — | — | |
| Income Taxes Paid, Net | — | — | — | — | — | — | $0 | $0 | $1.2m | — | — | |
| Additional Financial Items | ||||||||||||
| Accretion Expense | — | $783k | $1.5m | $17.7m | $5.8m | $8.6m | $8.9m | $15.8m | — | — | — | |
| Deconsolidation, Gain (Loss), Amount | — | $19.3m | — | — | — | $0 | $1.2m | $178.3m | $0 | — | — | |
| Equity Securities, FV-NI, Gain (Loss) | — | — | $0 | $0 | $29.9m | ($8.2m) | $18.3m | $8.1m | $0 | — | — | |
| Equity Securities, FV-NI, Realized Gain (Loss) | — | — | $0 | $0 | $2.2m | $3.7m | $8.7m | $8.1m | $0 | — | — | |
| Equity Securities, FV-NI, Unrealized Gain (Loss) | — | — | $0 | $0 | ($29.9m) | $8.2m | $9.6m | $0 | $0 | — | — | |
| Gain (Loss) on Disposition of Assets | — | — | — | $1.3m | ($804k) | ($6.3m) | $0 | $0 | — | — | — | |
| General and Administrative Expense | — | $43.6m | $94.4m | $145.7m | — | — | — | — | — | — | — | |
| Income Tax Expense (Benefit) | — | — | — | — | — | — | — | $1.2m | $435k | — | — | |
| Interest Expense Nonoperating | — | — | — | — | — | — | — | $99.3m | $53.1m | — | — | |
| Investment Income, Interest | — | $2.0m | $8.9m | $4.0m | $1.1m | $7.5m | $18.0m | $17.2m | $19.9m | — | — | |
| Operating Expenses | — | $183.7m | $306.8m | $482.7m | — | — | — | — | — | — | — | |
| Proceeds from Noncontrolling Interests | — | — | $23.9m | $24.1m | — | $0 | — | — | — | — | — | |
| Proceeds from (Payments to) Noncontrolling Interests | — | — | — | — | — | — | — | — | $2.1m | — | — | |
| Noncash interest expense on deferred royalty obligations | — | — | — | — | — | — | $0 | $8.3m | $125.1m | — | — | |
| Noncash lease expense | — | — | — | $3.1m | $5.6m | $5.2m | $4.0m | $4.1m | $4.9m | — | — | |
| Change in fair value of the embedded derivative associated with the deferred royalty obligation | — | — | — | — | — | — | $0 | ($1.6m) | ($19.7m) | — | — | |
| (Gain) loss on deconsolidation of subsidiaries | — | — | — | — | — | $0 | $1.2m | ($178.3m) | $0 | — | — | |
| Gain from investment in equity securities, net | — | — | $0 | $0 | ($29.9m) | $8.2m | ($18.3m) | ($8.1m) | $0 | — | — | |
| Accrual of payment-in-kind interest on term loan | — | — | — | $0 | $0 | $13.6m | $10.2m | $0 | $0 | — | — | |
| Other noncash adjustments, net | $260k | $442k | $1.4m | $2.7m | $7.1m | $604k | $181k | ($2.8m) | ($1.7m) | — | — | |
| Operating lease liabilities | — | — | — | ($3.5m) | ($6.1m) | ($6.2m) | ($4.8m) | ($5.9m) | ($6.5m) | — | — | |
| Payment for intangible assets | — | — | — | $0 | ($35.0m) | ($1.5m) | $0 | ($8.0m) | ($8.5m) | — | — | |
| Decrease in cash and cash equivalents resulting from deconsolidation of subsidiaries | — | ($2.9m) | — | — | — | $0 | ($503k) | ($140k) | $0 | — | — | |
| Proceeds from issuance of 2031 Notes | — | — | — | $550.0m | $747.5m | $0 | $0 | $0 | $575.0m | — | — | |
| Issuance costs and discounts associated with 2031 Notes/ Issuance costs and discounts associated with term loan under Amended Financing Agreement | — | — | — | ($13.0m) | ($16.1m) | $0 | $0 | ($16.0m) | ($12.0m) | — | — | |
| Proceeds from royalty obligation | — | — | — | — | — | — | $0 | $500.0m | $300.0m | — | — | |
| Issuance costs and discounts associated with a royalty obligation | — | — | — | — | — | — | $0 | ($27.5m) | ($3.0m) | — | — | |
| Proceeds from term loan under the Amended Financing Agreement | — | — | — | — | — | — | $0 | $450.0m | $0 | — | — | |
| Repayment of term loans | — | ($1.1m) | — | — | ($124.1m) | ($20.5m) | $0 | ($473.4m) | ($459.0m) | — | — | |
| Repayments of deferred royalty obligations | — | — | — | — | — | — | $0 | $0 | ($15.5m) | — | — | |
| Proceeds from stock option exercises, net of repurchases | $144k | $440k | $1.8m | $12.9m | $16.6m | $666k | $6.0m | $3.7m | $27.7m | — | — | |
| Transactions with noncontrolling interests | — | — | — | — | $3.5m | $0 | ($801k) | $0 | $2.1m | — | — | |
| Repurchase of RSU shares to satisfy tax withholding | — | — | — | ($714k) | ($4.7m) | ($1.6m) | ($6.9m) | ($7.5m) | ($14.2m) | — | — | |
| Transfers to noncontrolling interests | ($8.2m) | $21.6m | ($28.6m) | $12.0m | ($2.1m) | ($3.5m) | ($10.5m) | ($5.8m) | ($5.6m) | — | — | |
| Cash and cash equivalents | — | — | — | $356.1m | $393.8m | $376.7m | $375.9m | $681.1m | $570.1m | — | $542.7m | |
| Accretion expense (Notes 5 and 6) | — | — | — | $294k | $13k | $7k | $56k | $5k | $154k | $78k | — | |
| Changes in fair values of warrant liabilities (Notes 9(a) and 9(b)) | — | — | — | — | — | — | ($5k) | $138k | $33k | ($198k) | — | |
| Financial guarantee liability (Note 16(c)) | — | — | — | — | $182k | $901k | $24k | $34k | ($759k) | $30k | — | |
| Income Before Tax | — | — | — | ($11k) | ($39k) | $238k | $203k | $26k | $275k | ($201k) | — | |
| Gain on extinguishment of loan | — | — | — | — | — | — | — | $0 | $0 | ($10k) | — | |
| Interest expense | — | — | — | — | — | — | $0 | $0 | $65k | ($44k) | — | |
| Penalties recovery | — | — | — | — | — | — | $0 | $0 | ($305k) | $0 | — | |
| Settlements and legal provisions, net (Note 16(a)) | — | — | — | — | — | — | $0 | ($130k) | ($557k) | $0 | — | |
| Due to related parties | — | — | — | ($329k) | $70k | ($517k) | $475k | $1.2m | $573k | $961k | — | |
| Proceeds from Stock Issuance | — | — | — | — | — | — | $647k | $2.2m | $705k | $0 | — | |
| Proceeds from subscriptions received (Notes 8(d), 8(j) and 14) | — | — | — | — | — | $0 | $74k | $0 | $43k | $198k | — | |
| Proceeds from subscriptions received by MedMelior (Note 11) | — | — | — | — | — | $0 | $429k | $0 | $20k | $0 | — | |
| Repayment of loans payable (Note 6) | — | — | — | — | — | — | — | $0 | $0 | ($5k) | — | |
| Net Change in Cash | — | — | — | $2k | $20k | ($12k) | $2k | ($56) | $8 | $582 | — | |
| Common shares issued for services | — | — | — | $185k | $1.4m | $116k | $30k | $0 | $0 | — | — | |
| Common shares of MedMelior issued for services (Note 12) | — | — | — | — | — | $0 | $3.0m | $0 | $0 | — | — | |
| Foreign exchange loss | — | — | — | — | — | — | $203k | $26k | $275k | — | — | |
| Proceeds from issuance of common shares and warrants by MedMelior (Note 12) | — | — | — | — | — | $0 | $186k | $0 | $0 | — | — | |
| Change in unrealized gains/losses on warrant liabilities (Notes 10(a) and 10(b)) | — | — | — | — | $74k | ($131k) | ($5k) | $138k | — | — | — | |
| Other income - premium on loans payable (Note 8) | — | — | — | — | — | ($51k) | $0 | $0 | — | — | — | |
| Settlements and legal provisions, net (Notes 15 and 18) | — | — | — | — | — | $0 | $0 | ($130k) | — | — | — | |
| Proceeds from issuance of common shares and warrants, net (Note 9) | — | — | — | $16.3m | $1.3m | $11.4m | $647k | $2.2m | — | — | — | |
| Proceeds from loans payable (Note 8) | — | — | — | — | — | $120k | $0 | $0 | — | — | — | |
| Proceeds from (repayment of) convertible debenture (Note 7) | — | — | — | ($3.2m) | $600k | ($250k) | $0 | $300k | — | — | — | |
| Shelf prospectus transaction costs (Note 9(m)) | — | — | — | — | — | ($77k) | $0 | $0 | — | — | — | |
| Gain (loss) on sale/abandonment of assets, net | — | — | — | $1.3m | ($804k) | — | — | — | — | — | — | |
| Amounts receivable | — | — | — | ($93k) | ($350k) | ($181k) | — | — | — | — | — | |
| Lease payments | — | — | — | ($560k) | ($500k) | — | — | — | — | — | — | |
| Cash Flow From Continuing Financing Activities | — | — | — | — | — | ($13.1m) | $451.5m | $748.5m | $359.3m | — | $848.9m | |
| Cash Flow From Continuing Investing Activities | — | — | — | — | — | $453.1m | $54.0m | $60.8m | ($24.5m) | — | ($65.6m) | |
| Change In Account Payable | — | — | — | — | — | ($349k) | $2.8m | $1.5m | $26.6m | — | $1.9m | |
| Change In Cash Supplemental As Reported | — | — | — | — | — | $20.5m | ($22.2m) | $288.5m | ($111.1m) | — | — | |
| Change In Other Working Capital | — | — | — | — | — | $15.3m | ($1.9m) | $26.1m | $66.4m | — | $66.6m | |
| Change In Payable | — | — | — | — | — | ($349k) | $2.8m | $1.5m | $26.6m | — | $1.9m | |
| Change In Prepaid Assets | — | — | — | — | — | $7.7m | ($2.7m) | ($13.9m) | ($8.8m) | — | ($27.1m) | |
| Changes In Cash | — | — | — | — | — | $20.5m | ($22.2m) | $288.5m | ($111.1m) | — | $339.3m | |
| End Cash Position | — | — | — | — | — | $416.9m | $394.7m | $683.2m | $572.1m | — | $882.0m | |
| Financing Cash Flow | — | — | — | — | — | ($13.1m) |
$451.5m
+3537.91%
|
$748.5m
+65.76%
|
$359.3m
-52.00%
|
— | $848.9m | |
| Free Cash Flow | — | — | — | — | — | ($425.8m) | ($529.0m) | ($529.6m) | ($455.5m) | — | ($452.0m) | |
| Gain Loss On Investment Securities | — | — | — | — | — | $8.2m | ($18.3m) | ($8.1m) | ($8.8m) | — | ($2.3m) | |
| Gain Loss On Sale Of Business | — | — | — | — | — | $0 | $1.2m | ($178.3m) | $0 | — | ($52.0m) | |
| Investing Cash Flow | — | — | — | — | — | $453.1m | $54.0m | $60.8m | ($24.5m) | — | ($65.6m) | |
| Net Business Purchase And Sale | — | — | — | — | — | $0 | ($503k) | ($140k) | $0 | — | ($42k) | |
| Net Intangibles Purchase And Sale | — | — | — | — | — | ($1.5m) | $0 | ($8.0m) | ($8.5m) | — | ($6.9m) | |
| Net Investment Purchase And Sale | — | — | — | — | — | $339.5m | $55.8m | $44.1m | ($17.2m) | — | ($59.9m) | |
| Net PPE Purchase And Sale | — | — | — | — | — | ($4.8m) | ($1.3m) | ($933k) | ($1.1m) | — | ($1.2m) | |
| Operating Gains Losses | — | — | — | — | — | $14.5m | ($17.1m) | ($128.7m) | $84.9m | — | $66.5m | |
| Other Non Cash Items | — | — | — | — | — | ($88.5m) | $23.1m | $19.9m | $136.0m | — | — | |
| Proceeds From Stock Option Exercised | — | — | — | — | — | $3.2m | $9.4m | $8.2m | $34.1m | — | $56.4m | |
| Purchase Of Business | — | — | — | — | — | $0 | ($503k) | ($140k) | $0 | — | ($42k) | |
| Purchase Of Intangibles | — | — | — | — | — | ($1.5m) | $0 | ($8.0m) | ($8.5m) | — | ($6.9m) | |
| Purchase Of Investment | — | — | — | — | — | ($193.1m) | ($137.3m) | ($114.1m) | ($28.2m) | — | ($80.9m) | |
| Purchase Of PPE | — | — | $2.6m | $7.5m | $13.2m | ($4.8m) | ($1.3m) | ($933k) | ($1.1m) | — | ($8.1m) | |
| Sale Of Investment | — | — | — | — | — | $532.5m | $193.1m | $158.2m | $11.0m | — | $21.0m | |
| Unrealized Gain Loss On Investment Securities | — | — | — | — | — | — | ($803k) | ($2.5m) | ($21.3m) | — | ($19.2m) |